nodes	percent_of_prediction	percent_of_DWPC	metapath
Nefazodone—CYP3A7-CYP3A51P—Simvastatin—atherosclerosis	0.0552	0.0807	CbGbCtD
Nefazodone—CYP3A7—Simvastatin—atherosclerosis	0.0552	0.0807	CbGbCtD
Nefazodone—CYP3A7-CYP3A51P—Lovastatin—atherosclerosis	0.054	0.079	CbGbCtD
Nefazodone—CYP3A7—Lovastatin—atherosclerosis	0.054	0.079	CbGbCtD
Nefazodone—CYP3A5—Rosuvastatin—atherosclerosis	0.0446	0.0651	CbGbCtD
Nefazodone—CYP3A5—Simvastatin—atherosclerosis	0.0414	0.0605	CbGbCtD
Nefazodone—CYP3A5—Lovastatin—atherosclerosis	0.0405	0.0592	CbGbCtD
Nefazodone—CYP3A5—Pravastatin—atherosclerosis	0.0405	0.0592	CbGbCtD
Nefazodone—CYP2D6—Niacin—atherosclerosis	0.0321	0.047	CbGbCtD
Nefazodone—ABCB1—Ezetimibe—atherosclerosis	0.029	0.0424	CbGbCtD
Nefazodone—ABCB1—Simvastatin—atherosclerosis	0.027	0.0394	CbGbCtD
Nefazodone—ABCB1—Pravastatin—atherosclerosis	0.0264	0.0386	CbGbCtD
Nefazodone—ABCB1—Lovastatin—atherosclerosis	0.0264	0.0386	CbGbCtD
Nefazodone—CYP2D6—Simvastatin—atherosclerosis	0.0254	0.0371	CbGbCtD
Nefazodone—CYP2D6—Pravastatin—atherosclerosis	0.0249	0.0363	CbGbCtD
Nefazodone—CYP2D6—Lovastatin—atherosclerosis	0.0249	0.0363	CbGbCtD
Nefazodone—CYP3A4—Rosuvastatin—atherosclerosis	0.0174	0.0254	CbGbCtD
Nefazodone—CYP3A4—Ezetimibe—atherosclerosis	0.0174	0.0254	CbGbCtD
Nefazodone—CYP3A4—Simvastatin—atherosclerosis	0.0162	0.0236	CbGbCtD
Nefazodone—CYP3A4—Pravastatin—atherosclerosis	0.0158	0.0231	CbGbCtD
Nefazodone—CYP3A4—Lovastatin—atherosclerosis	0.0158	0.0231	CbGbCtD
Nefazodone—Cetirizine—HRH1—atherosclerosis	0.00141	0.19	CrCbGaD
Nefazodone—HTR2A—arteriole—atherosclerosis	0.00138	0.212	CbGeAlD
Nefazodone—Meclizine—HRH1—atherosclerosis	0.00118	0.159	CrCbGaD
Nefazodone—Hydroxyzine—HRH1—atherosclerosis	0.00109	0.147	CrCbGaD
Nefazodone—HTR2A—vein—atherosclerosis	0.000823	0.126	CbGeAlD
Nefazodone—Zuclopenthixol—HRH1—atherosclerosis	0.000586	0.079	CrCbGaD
Nefazodone—HTR2A—hindlimb—atherosclerosis	0.000547	0.0838	CbGeAlD
Nefazodone—Aripiprazole—HRH1—atherosclerosis	0.000542	0.0731	CrCbGaD
Nefazodone—Trazodone—HRH1—atherosclerosis	0.000539	0.0727	CrCbGaD
Nefazodone—Prochlorperazine—HRH1—atherosclerosis	0.000483	0.0651	CrCbGaD
Nefazodone—HTR2A—appendage—atherosclerosis	0.000469	0.0719	CbGeAlD
Nefazodone—Infection—Rosuvastatin—atherosclerosis	0.000456	0.00214	CcSEcCtD
Nefazodone—Visual impairment—Niacin—atherosclerosis	0.000453	0.00212	CcSEcCtD
Nefazodone—Alopecia—Simvastatin—atherosclerosis	0.000452	0.00212	CcSEcCtD
Nefazodone—Back pain—Ezetimibe—atherosclerosis	0.000452	0.00212	CcSEcCtD
Nefazodone—Muscle spasms—Ezetimibe—atherosclerosis	0.000449	0.00211	CcSEcCtD
Nefazodone—Thrombocytopenia—Rosuvastatin—atherosclerosis	0.000449	0.00211	CcSEcCtD
Nefazodone—Vision blurred—Lovastatin—atherosclerosis	0.000449	0.00211	CcSEcCtD
Nefazodone—Tremor—Lovastatin—atherosclerosis	0.000446	0.00209	CcSEcCtD
Nefazodone—Visual impairment—Pravastatin—atherosclerosis	0.000446	0.00209	CcSEcCtD
Nefazodone—Ill-defined disorder—Lovastatin—atherosclerosis	0.000442	0.00207	CcSEcCtD
Nefazodone—Flatulence—Simvastatin—atherosclerosis	0.000439	0.00206	CcSEcCtD
Nefazodone—Tinnitus—Niacin—atherosclerosis	0.000438	0.00206	CcSEcCtD
Nefazodone—Erythema multiforme—Pravastatin—atherosclerosis	0.000438	0.00205	CcSEcCtD
Nefazodone—Fluphenazine—HRH1—atherosclerosis	0.000437	0.0589	CrCbGaD
Nefazodone—Dysgeusia—Simvastatin—atherosclerosis	0.000437	0.00205	CcSEcCtD
Nefazodone—Flushing—Niacin—atherosclerosis	0.000436	0.00205	CcSEcCtD
Nefazodone—Angioedema—Lovastatin—atherosclerosis	0.000435	0.00204	CcSEcCtD
Nefazodone—Ill-defined disorder—Ezetimibe—atherosclerosis	0.000434	0.00203	CcSEcCtD
Nefazodone—Anaemia—Ezetimibe—atherosclerosis	0.000432	0.00203	CcSEcCtD
Nefazodone—Tinnitus—Pravastatin—atherosclerosis	0.000432	0.00202	CcSEcCtD
Nefazodone—Malaise—Lovastatin—atherosclerosis	0.00043	0.00202	CcSEcCtD
Nefazodone—Flushing—Pravastatin—atherosclerosis	0.00043	0.00201	CcSEcCtD
Nefazodone—Muscle spasms—Simvastatin—atherosclerosis	0.000429	0.00201	CcSEcCtD
Nefazodone—Vertigo—Lovastatin—atherosclerosis	0.000428	0.00201	CcSEcCtD
Nefazodone—Angioedema—Ezetimibe—atherosclerosis	0.000427	0.002	CcSEcCtD
Nefazodone—Leukopenia—Lovastatin—atherosclerosis	0.000427	0.002	CcSEcCtD
Nefazodone—Chills—Niacin—atherosclerosis	0.000422	0.00198	CcSEcCtD
Nefazodone—Malaise—Ezetimibe—atherosclerosis	0.000422	0.00198	CcSEcCtD
Nefazodone—Vision blurred—Simvastatin—atherosclerosis	0.00042	0.00197	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.000418	0.00196	CcSEcCtD
Nefazodone—Tremor—Simvastatin—atherosclerosis	0.000418	0.00196	CcSEcCtD
Nefazodone—Alopecia—Niacin—atherosclerosis	0.000415	0.00195	CcSEcCtD
Nefazodone—Chills—Pravastatin—atherosclerosis	0.000415	0.00195	CcSEcCtD
Nefazodone—Insomnia—Rosuvastatin—atherosclerosis	0.000415	0.00195	CcSEcCtD
Nefazodone—Ill-defined disorder—Simvastatin—atherosclerosis	0.000414	0.00194	CcSEcCtD
Nefazodone—Palpitations—Ezetimibe—atherosclerosis	0.000413	0.00194	CcSEcCtD
Nefazodone—Paraesthesia—Rosuvastatin—atherosclerosis	0.000412	0.00193	CcSEcCtD
Nefazodone—Anaemia—Simvastatin—atherosclerosis	0.000412	0.00193	CcSEcCtD
Nefazodone—Alopecia—Pravastatin—atherosclerosis	0.000409	0.00192	CcSEcCtD
Nefazodone—Cough—Ezetimibe—atherosclerosis	0.000408	0.00191	CcSEcCtD
Nefazodone—Angioedema—Simvastatin—atherosclerosis	0.000407	0.00191	CcSEcCtD
Nefazodone—Chest pain—Lovastatin—atherosclerosis	0.000406	0.0019	CcSEcCtD
Nefazodone—Arthralgia—Lovastatin—atherosclerosis	0.000406	0.0019	CcSEcCtD
Nefazodone—Myalgia—Lovastatin—atherosclerosis	0.000406	0.0019	CcSEcCtD
Nefazodone—Anxiety—Lovastatin—atherosclerosis	0.000404	0.0019	CcSEcCtD
Nefazodone—Dyspepsia—Rosuvastatin—atherosclerosis	0.000404	0.00189	CcSEcCtD
Nefazodone—Hypertension—Ezetimibe—atherosclerosis	0.000404	0.00189	CcSEcCtD
Nefazodone—Flatulence—Niacin—atherosclerosis	0.000403	0.00189	CcSEcCtD
Nefazodone—Malaise—Simvastatin—atherosclerosis	0.000402	0.00188	CcSEcCtD
Nefazodone—Discomfort—Lovastatin—atherosclerosis	0.000401	0.00188	CcSEcCtD
Nefazodone—Vertigo—Simvastatin—atherosclerosis	0.0004	0.00188	CcSEcCtD
Nefazodone—Leukopenia—Simvastatin—atherosclerosis	0.000399	0.00187	CcSEcCtD
Nefazodone—Myalgia—Ezetimibe—atherosclerosis	0.000398	0.00187	CcSEcCtD
Nefazodone—Arthralgia—Ezetimibe—atherosclerosis	0.000398	0.00187	CcSEcCtD
Nefazodone—Chest pain—Ezetimibe—atherosclerosis	0.000398	0.00187	CcSEcCtD
Nefazodone—Flatulence—Pravastatin—atherosclerosis	0.000397	0.00186	CcSEcCtD
Nefazodone—Dry mouth—Lovastatin—atherosclerosis	0.000397	0.00186	CcSEcCtD
Nefazodone—Dysgeusia—Pravastatin—atherosclerosis	0.000395	0.00185	CcSEcCtD
Nefazodone—Muscle spasms—Niacin—atherosclerosis	0.000394	0.00185	CcSEcCtD
Nefazodone—Discomfort—Ezetimibe—atherosclerosis	0.000393	0.00184	CcSEcCtD
Nefazodone—Constipation—Rosuvastatin—atherosclerosis	0.000392	0.00184	CcSEcCtD
Nefazodone—Pain—Rosuvastatin—atherosclerosis	0.000392	0.00184	CcSEcCtD
Nefazodone—Confusional state—Lovastatin—atherosclerosis	0.000392	0.00184	CcSEcCtD
Nefazodone—Dry mouth—Ezetimibe—atherosclerosis	0.000389	0.00182	CcSEcCtD
Nefazodone—Anaphylactic shock—Lovastatin—atherosclerosis	0.000389	0.00182	CcSEcCtD
Nefazodone—Muscle spasms—Pravastatin—atherosclerosis	0.000387	0.00182	CcSEcCtD
Nefazodone—Infection—Lovastatin—atherosclerosis	0.000386	0.00181	CcSEcCtD
Nefazodone—Vision blurred—Niacin—atherosclerosis	0.000386	0.00181	CcSEcCtD
Nefazodone—Confusional state—Ezetimibe—atherosclerosis	0.000385	0.0018	CcSEcCtD
Nefazodone—Anaphylactic shock—Ezetimibe—atherosclerosis	0.000381	0.00179	CcSEcCtD
Nefazodone—Thrombocytopenia—Lovastatin—atherosclerosis	0.000381	0.00179	CcSEcCtD
Nefazodone—Vision blurred—Pravastatin—atherosclerosis	0.00038	0.00178	CcSEcCtD
Nefazodone—Arthralgia—Simvastatin—atherosclerosis	0.00038	0.00178	CcSEcCtD
Nefazodone—Chest pain—Simvastatin—atherosclerosis	0.00038	0.00178	CcSEcCtD
Nefazodone—Myalgia—Simvastatin—atherosclerosis	0.00038	0.00178	CcSEcCtD
Nefazodone—Infection—Ezetimibe—atherosclerosis	0.000379	0.00178	CcSEcCtD
Nefazodone—Feeling abnormal—Rosuvastatin—atherosclerosis	0.000378	0.00177	CcSEcCtD
Nefazodone—Anxiety—Simvastatin—atherosclerosis	0.000378	0.00177	CcSEcCtD
Nefazodone—Tremor—Pravastatin—atherosclerosis	0.000378	0.00177	CcSEcCtD
Nefazodone—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000375	0.00176	CcSEcCtD
Nefazodone—Discomfort—Simvastatin—atherosclerosis	0.000375	0.00176	CcSEcCtD
Nefazodone—Angioedema—Niacin—atherosclerosis	0.000374	0.00175	CcSEcCtD
Nefazodone—Ill-defined disorder—Pravastatin—atherosclerosis	0.000374	0.00175	CcSEcCtD
Nefazodone—Thrombocytopenia—Ezetimibe—atherosclerosis	0.000374	0.00175	CcSEcCtD
Nefazodone—Anaemia—Pravastatin—atherosclerosis	0.000372	0.00175	CcSEcCtD
Nefazodone—Anorexia—Lovastatin—atherosclerosis	0.000371	0.00174	CcSEcCtD
Nefazodone—Angioedema—Pravastatin—atherosclerosis	0.000368	0.00173	CcSEcCtD
Nefazodone—Vertigo—Niacin—atherosclerosis	0.000368	0.00172	CcSEcCtD
Nefazodone—Syncope—Niacin—atherosclerosis	0.000367	0.00172	CcSEcCtD
Nefazodone—Confusional state—Simvastatin—atherosclerosis	0.000367	0.00172	CcSEcCtD
Nefazodone—Leukopenia—Niacin—atherosclerosis	0.000366	0.00172	CcSEcCtD
Nefazodone—Urticaria—Rosuvastatin—atherosclerosis	0.000365	0.00171	CcSEcCtD
Nefazodone—Oedema—Simvastatin—atherosclerosis	0.000364	0.00171	CcSEcCtD
Nefazodone—Anaphylactic shock—Simvastatin—atherosclerosis	0.000364	0.00171	CcSEcCtD
Nefazodone—Malaise—Pravastatin—atherosclerosis	0.000363	0.0017	CcSEcCtD
Nefazodone—Abdominal pain—Rosuvastatin—atherosclerosis	0.000363	0.0017	CcSEcCtD
Nefazodone—Vertigo—Pravastatin—atherosclerosis	0.000362	0.0017	CcSEcCtD
Nefazodone—Palpitations—Niacin—atherosclerosis	0.000362	0.0017	CcSEcCtD
Nefazodone—Infection—Simvastatin—atherosclerosis	0.000361	0.00169	CcSEcCtD
Nefazodone—Leukopenia—Pravastatin—atherosclerosis	0.000361	0.00169	CcSEcCtD
Nefazodone—Loss of consciousness—Niacin—atherosclerosis	0.00036	0.00169	CcSEcCtD
Nefazodone—Cough—Niacin—atherosclerosis	0.000357	0.00167	CcSEcCtD
Nefazodone—Thrombocytopenia—Simvastatin—atherosclerosis	0.000356	0.00167	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.000354	0.00166	CcSEcCtD
Nefazodone—Insomnia—Lovastatin—atherosclerosis	0.000352	0.00165	CcSEcCtD
Nefazodone—Cough—Pravastatin—atherosclerosis	0.000352	0.00165	CcSEcCtD
Nefazodone—Paraesthesia—Lovastatin—atherosclerosis	0.000349	0.00164	CcSEcCtD
Nefazodone—Trifluoperazine—HRH1—atherosclerosis	0.000349	0.0471	CrCbGaD
Nefazodone—Arthralgia—Niacin—atherosclerosis	0.000348	0.00163	CcSEcCtD
Nefazodone—Myalgia—Niacin—atherosclerosis	0.000348	0.00163	CcSEcCtD
Nefazodone—Hypertension—Pravastatin—atherosclerosis	0.000348	0.00163	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.000348	0.00163	CcSEcCtD
Nefazodone—Anorexia—Simvastatin—atherosclerosis	0.000347	0.00163	CcSEcCtD
Nefazodone—Dyspnoea—Lovastatin—atherosclerosis	0.000347	0.00163	CcSEcCtD
Nefazodone—Perphenazine—HRH1—atherosclerosis	0.000345	0.0466	CrCbGaD
Nefazodone—Insomnia—Ezetimibe—atherosclerosis	0.000345	0.00162	CcSEcCtD
Nefazodone—Myalgia—Pravastatin—atherosclerosis	0.000343	0.00161	CcSEcCtD
Nefazodone—Chest pain—Pravastatin—atherosclerosis	0.000343	0.00161	CcSEcCtD
Nefazodone—Arthralgia—Pravastatin—atherosclerosis	0.000343	0.00161	CcSEcCtD
Nefazodone—Paraesthesia—Ezetimibe—atherosclerosis	0.000343	0.00161	CcSEcCtD
Nefazodone—Dyspepsia—Lovastatin—atherosclerosis	0.000342	0.00161	CcSEcCtD
Nefazodone—Anxiety—Pravastatin—atherosclerosis	0.000342	0.0016	CcSEcCtD
Nefazodone—Dry mouth—Niacin—atherosclerosis	0.000341	0.0016	CcSEcCtD
Nefazodone—Dyspnoea—Ezetimibe—atherosclerosis	0.00034	0.00159	CcSEcCtD
Nefazodone—Discomfort—Pravastatin—atherosclerosis	0.000339	0.00159	CcSEcCtD
Nefazodone—Quetiapine—HRH1—atherosclerosis	0.000339	0.0457	CrCbGaD
Nefazodone—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000338	0.00159	CcSEcCtD
Nefazodone—Decreased appetite—Lovastatin—atherosclerosis	0.000338	0.00159	CcSEcCtD
Nefazodone—Dyspepsia—Ezetimibe—atherosclerosis	0.000336	0.00157	CcSEcCtD
Nefazodone—HTR2A—artery—atherosclerosis	0.000335	0.0514	CbGeAlD
Nefazodone—Oedema—Niacin—atherosclerosis	0.000334	0.00157	CcSEcCtD
Nefazodone—Anaphylactic shock—Niacin—atherosclerosis	0.000334	0.00157	CcSEcCtD
Nefazodone—Pain—Lovastatin—atherosclerosis	0.000333	0.00156	CcSEcCtD
Nefazodone—Constipation—Lovastatin—atherosclerosis	0.000333	0.00156	CcSEcCtD
Nefazodone—Confusional state—Pravastatin—atherosclerosis	0.000332	0.00155	CcSEcCtD
Nefazodone—Decreased appetite—Ezetimibe—atherosclerosis	0.000332	0.00155	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.000331	0.00155	CcSEcCtD
Nefazodone—Asthenia—Rosuvastatin—atherosclerosis	0.000329	0.00154	CcSEcCtD
Nefazodone—Insomnia—Simvastatin—atherosclerosis	0.000329	0.00154	CcSEcCtD
Nefazodone—Anaphylactic shock—Pravastatin—atherosclerosis	0.000329	0.00154	CcSEcCtD
Nefazodone—Oedema—Pravastatin—atherosclerosis	0.000329	0.00154	CcSEcCtD
Nefazodone—Shock—Niacin—atherosclerosis	0.000329	0.00154	CcSEcCtD
Nefazodone—Infection—Pravastatin—atherosclerosis	0.000327	0.00153	CcSEcCtD
Nefazodone—Paraesthesia—Simvastatin—atherosclerosis	0.000327	0.00153	CcSEcCtD
Nefazodone—Pain—Ezetimibe—atherosclerosis	0.000326	0.00153	CcSEcCtD
Nefazodone—Constipation—Ezetimibe—atherosclerosis	0.000326	0.00153	CcSEcCtD
Nefazodone—Tachycardia—Niacin—atherosclerosis	0.000326	0.00153	CcSEcCtD
Nefazodone—Pruritus—Rosuvastatin—atherosclerosis	0.000325	0.00152	CcSEcCtD
Nefazodone—Dyspnoea—Simvastatin—atherosclerosis	0.000324	0.00152	CcSEcCtD
Nefazodone—Hyperhidrosis—Niacin—atherosclerosis	0.000323	0.00151	CcSEcCtD
Nefazodone—Thrombocytopenia—Pravastatin—atherosclerosis	0.000322	0.00151	CcSEcCtD
Nefazodone—Feeling abnormal—Lovastatin—atherosclerosis	0.000321	0.0015	CcSEcCtD
Nefazodone—Dyspepsia—Simvastatin—atherosclerosis	0.00032	0.0015	CcSEcCtD
Nefazodone—Anorexia—Niacin—atherosclerosis	0.000318	0.00149	CcSEcCtD
Nefazodone—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000318	0.00149	CcSEcCtD
Nefazodone—Hyperhidrosis—Pravastatin—atherosclerosis	0.000318	0.00149	CcSEcCtD
Nefazodone—Decreased appetite—Simvastatin—atherosclerosis	0.000316	0.00148	CcSEcCtD
Nefazodone—Feeling abnormal—Ezetimibe—atherosclerosis	0.000314	0.00147	CcSEcCtD
Nefazodone—Diarrhoea—Rosuvastatin—atherosclerosis	0.000314	0.00147	CcSEcCtD
Nefazodone—Anorexia—Pravastatin—atherosclerosis	0.000314	0.00147	CcSEcCtD
Nefazodone—Hypotension—Niacin—atherosclerosis	0.000312	0.00146	CcSEcCtD
Nefazodone—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000312	0.00146	CcSEcCtD
Nefazodone—Pain—Simvastatin—atherosclerosis	0.000311	0.00146	CcSEcCtD
Nefazodone—Constipation—Simvastatin—atherosclerosis	0.000311	0.00146	CcSEcCtD
Nefazodone—Urticaria—Lovastatin—atherosclerosis	0.000309	0.00145	CcSEcCtD
Nefazodone—Abdominal pain—Lovastatin—atherosclerosis	0.000307	0.00144	CcSEcCtD
Nefazodone—Body temperature increased—Lovastatin—atherosclerosis	0.000307	0.00144	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Niacin—atherosclerosis	0.000304	0.00143	CcSEcCtD
Nefazodone—Dizziness—Rosuvastatin—atherosclerosis	0.000303	0.00142	CcSEcCtD
Nefazodone—Urticaria—Ezetimibe—atherosclerosis	0.000303	0.00142	CcSEcCtD
Nefazodone—Insomnia—Niacin—atherosclerosis	0.000302	0.00142	CcSEcCtD
Nefazodone—Abdominal pain—Ezetimibe—atherosclerosis	0.000302	0.00141	CcSEcCtD
Nefazodone—Body temperature increased—Ezetimibe—atherosclerosis	0.000302	0.00141	CcSEcCtD
Nefazodone—Paraesthesia—Niacin—atherosclerosis	0.0003	0.00141	CcSEcCtD
Nefazodone—Feeling abnormal—Simvastatin—atherosclerosis	0.0003	0.00141	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.0003	0.00141	CcSEcCtD
Nefazodone—Dyspnoea—Niacin—atherosclerosis	0.000298	0.0014	CcSEcCtD
Nefazodone—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000297	0.00139	CcSEcCtD
Nefazodone—Insomnia—Pravastatin—atherosclerosis	0.000297	0.00139	CcSEcCtD
Nefazodone—Somnolence—Niacin—atherosclerosis	0.000297	0.00139	CcSEcCtD
Nefazodone—Paraesthesia—Pravastatin—atherosclerosis	0.000295	0.00138	CcSEcCtD
Nefazodone—Dyspepsia—Niacin—atherosclerosis	0.000294	0.00138	CcSEcCtD
Nefazodone—Dyspnoea—Pravastatin—atherosclerosis	0.000293	0.00137	CcSEcCtD
Nefazodone—Decreased appetite—Niacin—atherosclerosis	0.00029	0.00136	CcSEcCtD
Nefazodone—Dyspepsia—Pravastatin—atherosclerosis	0.00029	0.00136	CcSEcCtD
Nefazodone—Rash—Rosuvastatin—atherosclerosis	0.000289	0.00136	CcSEcCtD
Nefazodone—Dermatitis—Rosuvastatin—atherosclerosis	0.000289	0.00136	CcSEcCtD
Nefazodone—Urticaria—Simvastatin—atherosclerosis	0.000289	0.00136	CcSEcCtD
Nefazodone—Body temperature increased—Simvastatin—atherosclerosis	0.000288	0.00135	CcSEcCtD
Nefazodone—Abdominal pain—Simvastatin—atherosclerosis	0.000288	0.00135	CcSEcCtD
Nefazodone—Headache—Rosuvastatin—atherosclerosis	0.000288	0.00135	CcSEcCtD
Nefazodone—Hypersensitivity—Lovastatin—atherosclerosis	0.000287	0.00134	CcSEcCtD
Nefazodone—Decreased appetite—Pravastatin—atherosclerosis	0.000286	0.00134	CcSEcCtD
Nefazodone—Pain—Niacin—atherosclerosis	0.000286	0.00134	CcSEcCtD
Nefazodone—HTR2A—endothelium—atherosclerosis	0.000283	0.0434	CbGeAlD
Nefazodone—Constipation—Pravastatin—atherosclerosis	0.000281	0.00132	CcSEcCtD
Nefazodone—Pain—Pravastatin—atherosclerosis	0.000281	0.00132	CcSEcCtD
Nefazodone—Hypersensitivity—Ezetimibe—atherosclerosis	0.000281	0.00132	CcSEcCtD
Nefazodone—Asthenia—Lovastatin—atherosclerosis	0.000279	0.00131	CcSEcCtD
Nefazodone—Pruritus—Lovastatin—atherosclerosis	0.000275	0.00129	CcSEcCtD
Nefazodone—Asthenia—Ezetimibe—atherosclerosis	0.000274	0.00128	CcSEcCtD
Nefazodone—Gastrointestinal pain—Niacin—atherosclerosis	0.000273	0.00128	CcSEcCtD
Nefazodone—Nausea—Rosuvastatin—atherosclerosis	0.000273	0.00128	CcSEcCtD
Nefazodone—Feeling abnormal—Pravastatin—atherosclerosis	0.000271	0.00127	CcSEcCtD
Nefazodone—Pruritus—Ezetimibe—atherosclerosis	0.00027	0.00127	CcSEcCtD
Nefazodone—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000269	0.00126	CcSEcCtD
Nefazodone—Hypersensitivity—Simvastatin—atherosclerosis	0.000268	0.00126	CcSEcCtD
Nefazodone—Diarrhoea—Lovastatin—atherosclerosis	0.000266	0.00125	CcSEcCtD
Nefazodone—Urticaria—Niacin—atherosclerosis	0.000265	0.00124	CcSEcCtD
Nefazodone—Body temperature increased—Niacin—atherosclerosis	0.000264	0.00124	CcSEcCtD
Nefazodone—Abdominal pain—Niacin—atherosclerosis	0.000264	0.00124	CcSEcCtD
Nefazodone—Urticaria—Pravastatin—atherosclerosis	0.000261	0.00123	CcSEcCtD
Nefazodone—HTR2A—blood vessel—atherosclerosis	0.000261	0.04	CbGeAlD
Nefazodone—Asthenia—Simvastatin—atherosclerosis	0.000261	0.00122	CcSEcCtD
Nefazodone—Diarrhoea—Ezetimibe—atherosclerosis	0.000261	0.00122	CcSEcCtD
Nefazodone—Body temperature increased—Pravastatin—atherosclerosis	0.00026	0.00122	CcSEcCtD
Nefazodone—Abdominal pain—Pravastatin—atherosclerosis	0.00026	0.00122	CcSEcCtD
Nefazodone—Pruritus—Simvastatin—atherosclerosis	0.000257	0.00121	CcSEcCtD
Nefazodone—Dizziness—Lovastatin—atherosclerosis	0.000257	0.00121	CcSEcCtD
Nefazodone—CYP3A7—liver—atherosclerosis	0.000253	0.0387	CbGeAlD
Nefazodone—Dizziness—Ezetimibe—atherosclerosis	0.000252	0.00118	CcSEcCtD
Nefazodone—Diarrhoea—Simvastatin—atherosclerosis	0.000249	0.00117	CcSEcCtD
Nefazodone—Vomiting—Lovastatin—atherosclerosis	0.000247	0.00116	CcSEcCtD
Nefazodone—Hypersensitivity—Niacin—atherosclerosis	0.000246	0.00115	CcSEcCtD
Nefazodone—Rash—Lovastatin—atherosclerosis	0.000245	0.00115	CcSEcCtD
Nefazodone—Dermatitis—Lovastatin—atherosclerosis	0.000245	0.00115	CcSEcCtD
Nefazodone—Headache—Lovastatin—atherosclerosis	0.000244	0.00114	CcSEcCtD
Nefazodone—Vomiting—Ezetimibe—atherosclerosis	0.000243	0.00114	CcSEcCtD
Nefazodone—Hypersensitivity—Pravastatin—atherosclerosis	0.000242	0.00114	CcSEcCtD
Nefazodone—Dizziness—Simvastatin—atherosclerosis	0.000241	0.00113	CcSEcCtD
Nefazodone—Rash—Ezetimibe—atherosclerosis	0.000241	0.00113	CcSEcCtD
Nefazodone—Dermatitis—Ezetimibe—atherosclerosis	0.00024	0.00113	CcSEcCtD
Nefazodone—Asthenia—Niacin—atherosclerosis	0.00024	0.00112	CcSEcCtD
Nefazodone—Headache—Ezetimibe—atherosclerosis	0.000239	0.00112	CcSEcCtD
Nefazodone—Pruritus—Niacin—atherosclerosis	0.000236	0.00111	CcSEcCtD
Nefazodone—Asthenia—Pravastatin—atherosclerosis	0.000236	0.00111	CcSEcCtD
Nefazodone—Pruritus—Pravastatin—atherosclerosis	0.000233	0.00109	CcSEcCtD
Nefazodone—Vomiting—Simvastatin—atherosclerosis	0.000231	0.00108	CcSEcCtD
Nefazodone—Nausea—Lovastatin—atherosclerosis	0.000231	0.00108	CcSEcCtD
Nefazodone—Rash—Simvastatin—atherosclerosis	0.000229	0.00108	CcSEcCtD
Nefazodone—Dermatitis—Simvastatin—atherosclerosis	0.000229	0.00107	CcSEcCtD
Nefazodone—Diarrhoea—Niacin—atherosclerosis	0.000229	0.00107	CcSEcCtD
Nefazodone—Headache—Simvastatin—atherosclerosis	0.000228	0.00107	CcSEcCtD
Nefazodone—Nausea—Ezetimibe—atherosclerosis	0.000227	0.00106	CcSEcCtD
Nefazodone—Diarrhoea—Pravastatin—atherosclerosis	0.000225	0.00106	CcSEcCtD
Nefazodone—Dizziness—Niacin—atherosclerosis	0.000221	0.00104	CcSEcCtD
Nefazodone—Dizziness—Pravastatin—atherosclerosis	0.000217	0.00102	CcSEcCtD
Nefazodone—Nausea—Simvastatin—atherosclerosis	0.000216	0.00101	CcSEcCtD
Nefazodone—CYP3A7-CYP3A51P—liver—atherosclerosis	0.000215	0.0329	CbGeAlD
Nefazodone—Vomiting—Niacin—atherosclerosis	0.000212	0.000996	CcSEcCtD
Nefazodone—Rash—Niacin—atherosclerosis	0.000211	0.000988	CcSEcCtD
Nefazodone—Dermatitis—Niacin—atherosclerosis	0.00021	0.000987	CcSEcCtD
Nefazodone—Headache—Niacin—atherosclerosis	0.000209	0.000981	CcSEcCtD
Nefazodone—Vomiting—Pravastatin—atherosclerosis	0.000209	0.000981	CcSEcCtD
Nefazodone—Rash—Pravastatin—atherosclerosis	0.000207	0.000972	CcSEcCtD
Nefazodone—Dermatitis—Pravastatin—atherosclerosis	0.000207	0.000971	CcSEcCtD
Nefazodone—Headache—Pravastatin—atherosclerosis	0.000206	0.000966	CcSEcCtD
Nefazodone—Nausea—Niacin—atherosclerosis	0.000198	0.00093	CcSEcCtD
Nefazodone—HTR1A—cardiovascular system—atherosclerosis	0.000196	0.03	CbGeAlD
Nefazodone—Nausea—Pravastatin—atherosclerosis	0.000195	0.000916	CcSEcCtD
Nefazodone—ADRA1A—cardiovascular system—atherosclerosis	0.00018	0.0276	CbGeAlD
Nefazodone—ABCB1—blood vessel—atherosclerosis	0.000171	0.0262	CbGeAlD
Nefazodone—ADRA1A—adipose tissue—atherosclerosis	0.000159	0.0244	CbGeAlD
Nefazodone—ADRA2A—connective tissue—atherosclerosis	0.000158	0.0241	CbGeAlD
Nefazodone—HTR2A—connective tissue—atherosclerosis	0.000134	0.0205	CbGeAlD
Nefazodone—CYP3A5—adipose tissue—atherosclerosis	0.000127	0.0194	CbGeAlD
Nefazodone—ADRA2A—adipose tissue—atherosclerosis	0.000121	0.0185	CbGeAlD
Nefazodone—Thioproperazine—ALB—atherosclerosis	0.000119	0.016	CrCbGaD
Nefazodone—HTR2A—cardiovascular system—atherosclerosis	0.000117	0.0179	CbGeAlD
Nefazodone—ADRA1A—liver—atherosclerosis	0.000111	0.0171	CbGeAlD
Nefazodone—CYP3A5—liver—atherosclerosis	8.89e-05	0.0136	CbGeAlD
Nefazodone—ABCB1—cardiovascular system—atherosclerosis	7.64e-05	0.0117	CbGeAlD
Nefazodone—HTR2A—liver—atherosclerosis	7.21e-05	0.011	CbGeAlD
Nefazodone—ABCB1—adipose tissue—atherosclerosis	6.74e-05	0.0103	CbGeAlD
Nefazodone—CYP3A4—liver—atherosclerosis	6.67e-05	0.0102	CbGeAlD
Nefazodone—CYP2D6—liver—atherosclerosis	6.57e-05	0.0101	CbGeAlD
Nefazodone—ABCB1—liver—atherosclerosis	4.72e-05	0.00724	CbGeAlD
Nefazodone—ADRA1B—Signaling Pathways—CAV1—atherosclerosis	8.53e-06	9.64e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—F2—atherosclerosis	8.53e-06	9.64e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—APOA1—atherosclerosis	8.51e-06	9.62e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—APOE—atherosclerosis	8.5e-06	9.6e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—F2—atherosclerosis	8.48e-06	9.59e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—LPL—atherosclerosis	8.48e-06	9.58e-05	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—ALB—atherosclerosis	8.44e-06	9.54e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—CAV1—atherosclerosis	8.42e-06	9.52e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—ABCA1—atherosclerosis	8.42e-06	9.51e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—APOA1—atherosclerosis	8.4e-06	9.49e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—MTHFR—atherosclerosis	8.37e-06	9.45e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PRKCG—atherosclerosis	8.24e-06	9.31e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PLA2G1B—atherosclerosis	8.22e-06	9.29e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—ESR1—atherosclerosis	8.22e-06	9.29e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PPARA—atherosclerosis	8.21e-06	9.27e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—PDGFB—atherosclerosis	8.17e-06	9.23e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—PIK3CG—atherosclerosis	8.16e-06	9.22e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—F2—atherosclerosis	8.12e-06	9.18e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—PIK3CG—atherosclerosis	8.12e-06	9.17e-05	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—NOS3—atherosclerosis	8.07e-06	9.12e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—SPP1—atherosclerosis	8.03e-06	9.07e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PDGFB—atherosclerosis	8e-06	9.04e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—CXCL8—atherosclerosis	8e-06	9.03e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—AGT—atherosclerosis	7.97e-06	9.01e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—AGT—atherosclerosis	7.95e-06	8.98e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—ALOX5—atherosclerosis	7.94e-06	8.97e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—MAPK3—atherosclerosis	7.82e-06	8.83e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—APOE—atherosclerosis	7.81e-06	8.83e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—LEP—atherosclerosis	7.81e-06	8.83e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—AGT—atherosclerosis	7.81e-06	8.82e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—APOE—atherosclerosis	7.79e-06	8.8e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—MAPK3—atherosclerosis	7.78e-06	8.79e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—PIK3CG—atherosclerosis	7.77e-06	8.78e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CAV1—atherosclerosis	7.74e-06	8.75e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—INS—atherosclerosis	7.73e-06	8.73e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—APOA1—atherosclerosis	7.72e-06	8.73e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—CAV1—atherosclerosis	7.72e-06	8.72e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—APOA1—atherosclerosis	7.7e-06	8.7e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—INS—atherosclerosis	7.69e-06	8.68e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PIK3CG—atherosclerosis	7.67e-06	8.67e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—HMOX1—atherosclerosis	7.67e-06	8.66e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—LEP—atherosclerosis	7.65e-06	8.64e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—APOE—atherosclerosis	7.65e-06	8.64e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CCL2—atherosclerosis	7.6e-06	8.59e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CAV1—atherosclerosis	7.58e-06	8.56e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—APOA1—atherosclerosis	7.56e-06	8.54e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CCL2—atherosclerosis	7.56e-06	8.54e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—IGF1—atherosclerosis	7.47e-06	8.44e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—ESR1—atherosclerosis	7.46e-06	8.43e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—MAPK3—atherosclerosis	7.44e-06	8.41e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—IGF1—atherosclerosis	7.43e-06	8.4e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PDGFB—atherosclerosis	7.43e-06	8.4e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PPARG—atherosclerosis	7.4e-06	8.37e-05	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—PTGS2—atherosclerosis	7.38e-06	8.34e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—F2—atherosclerosis	7.37e-06	8.32e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—INS—atherosclerosis	7.36e-06	8.31e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—APOB—atherosclerosis	7.34e-06	8.3e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—ESR1—atherosclerosis	7.3e-06	8.25e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—INS—atherosclerosis	7.26e-06	8.2e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—AGT—atherosclerosis	7.25e-06	8.2e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CCL2—atherosclerosis	7.24e-06	8.18e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—HMOX1—atherosclerosis	7.22e-06	8.16e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—AKT1—atherosclerosis	7.22e-06	8.16e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—F2—atherosclerosis	7.21e-06	8.15e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—GSTM1—atherosclerosis	7.14e-06	8.07e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—NAMPT—atherosclerosis	7.12e-06	8.05e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—IGF1—atherosclerosis	7.12e-06	8.04e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—APOE—atherosclerosis	7.11e-06	8.03e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—LEP—atherosclerosis	7.11e-06	8.03e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—SERPINE1—atherosclerosis	7.1e-06	8.02e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—LIPC—atherosclerosis	7.08e-06	8e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—SERPINE1—atherosclerosis	7.06e-06	7.98e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—PIK3CG—atherosclerosis	7.05e-06	7.97e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CAV1—atherosclerosis	7.04e-06	7.96e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—APOC3—atherosclerosis	7.04e-06	7.95e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PIK3CG—atherosclerosis	7.03e-06	7.94e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—APOA1—atherosclerosis	7.03e-06	7.94e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—LPL—atherosclerosis	7.01e-06	7.92e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—LDLR—atherosclerosis	6.99e-06	7.9e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—APOB—atherosclerosis	6.92e-06	7.82e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PIK3CG—atherosclerosis	6.9e-06	7.8e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—GPX1—atherosclerosis	6.84e-06	7.73e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CETP—atherosclerosis	6.83e-06	7.72e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—ESR1—atherosclerosis	6.79e-06	7.67e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PPARG—atherosclerosis	6.78e-06	7.67e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—NOS3—atherosclerosis	6.77e-06	7.65e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—SERPINE1—atherosclerosis	6.76e-06	7.64e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—MAPK3—atherosclerosis	6.75e-06	7.63e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—NOS3—atherosclerosis	6.74e-06	7.62e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—GSTM1—atherosclerosis	6.73e-06	7.61e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—F2—atherosclerosis	6.7e-06	7.57e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—INS—atherosclerosis	6.67e-06	7.54e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—CD36—atherosclerosis	6.66e-06	7.53e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—ALB—atherosclerosis	6.66e-06	7.52e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—INS—atherosclerosis	6.65e-06	7.52e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—MAPK3—atherosclerosis	6.61e-06	7.47e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—LPL—atherosclerosis	6.61e-06	7.47e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CCL2—atherosclerosis	6.57e-06	7.42e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—SCARB1—atherosclerosis	6.54e-06	7.39e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—INS—atherosclerosis	6.53e-06	7.38e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—IGF1—atherosclerosis	6.46e-06	7.29e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—NOS3—atherosclerosis	6.45e-06	7.29e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—GPX1—atherosclerosis	6.45e-06	7.28e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CCL2—atherosclerosis	6.43e-06	7.26e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PIK3CG—atherosclerosis	6.41e-06	7.25e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—NOS3—atherosclerosis	6.37e-06	7.19e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—IGF1—atherosclerosis	6.32e-06	7.14e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—MTHFR—atherosclerosis	6.31e-06	7.13e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—CD36—atherosclerosis	6.28e-06	7.09e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PPARA—atherosclerosis	6.19e-06	7e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—HMGCR—atherosclerosis	6.18e-06	6.98e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—MAPK3—atherosclerosis	6.14e-06	6.94e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—SERPINE1—atherosclerosis	6.13e-06	6.93e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—ALB—atherosclerosis	6.1e-06	6.89e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—INS—atherosclerosis	6.07e-06	6.86e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CXCL8—atherosclerosis	6.01e-06	6.79e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—SERPINE1—atherosclerosis	6e-06	6.78e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—AGT—atherosclerosis	6e-06	6.78e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CXCL8—atherosclerosis	5.98e-06	6.75e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CCL2—atherosclerosis	5.97e-06	6.75e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—MTHFR—atherosclerosis	5.95e-06	6.72e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—APOE—atherosclerosis	5.88e-06	6.64e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IGF1—atherosclerosis	5.87e-06	6.64e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—NOS3—atherosclerosis	5.85e-06	6.61e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PPARA—atherosclerosis	5.84e-06	6.59e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—NOS3—atherosclerosis	5.84e-06	6.59e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PTGS2—atherosclerosis	5.82e-06	6.58e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—CAV1—atherosclerosis	5.82e-06	6.58e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—APOA1—atherosclerosis	5.81e-06	6.56e-05	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—AKT1—atherosclerosis	5.81e-06	6.56e-05	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—AKT1—atherosclerosis	5.78e-06	6.53e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—NOS3—atherosclerosis	5.73e-06	6.47e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CXCL8—atherosclerosis	5.72e-06	6.47e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—IL6—atherosclerosis	5.71e-06	6.46e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—IL6—atherosclerosis	5.68e-06	6.42e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—AGT—atherosclerosis	5.65e-06	6.39e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—SERPINE1—atherosclerosis	5.58e-06	6.3e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—APOE—atherosclerosis	5.54e-06	6.26e-05	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—AKT1—atherosclerosis	5.53e-06	6.25e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—ABCA1—atherosclerosis	5.51e-06	6.22e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—CAV1—atherosclerosis	5.49e-06	6.2e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—APOA1—atherosclerosis	5.48e-06	6.19e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—IL6—atherosclerosis	5.44e-06	6.15e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—MMP9—atherosclerosis	5.44e-06	6.14e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—MMP9—atherosclerosis	5.41e-06	6.11e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—NFKB1—atherosclerosis	5.38e-06	6.08e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—NFKB1—atherosclerosis	5.35e-06	6.04e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PTGS2—atherosclerosis	5.34e-06	6.03e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—NOS3—atherosclerosis	5.32e-06	6.02e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PIK3CG—atherosclerosis	5.3e-06	5.99e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—MAPK8—atherosclerosis	5.29e-06	5.97e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—AKT1—atherosclerosis	5.27e-06	5.96e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—MAPK8—atherosclerosis	5.26e-06	5.94e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—AKT1—atherosclerosis	5.24e-06	5.93e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CXCL8—atherosclerosis	5.19e-06	5.87e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—MMP9—atherosclerosis	5.18e-06	5.85e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—NFKB1—atherosclerosis	5.12e-06	5.79e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PPARG—atherosclerosis	5.12e-06	5.78e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CXCL8—atherosclerosis	5.08e-06	5.74e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—MAPK8—atherosclerosis	5.03e-06	5.69e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—INS—atherosclerosis	5.02e-06	5.67e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—AKT1—atherosclerosis	5.02e-06	5.67e-05	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—AKT1—atherosclerosis	5.02e-06	5.67e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PIK3CG—atherosclerosis	5e-06	5.65e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—IL6—atherosclerosis	4.94e-06	5.58e-05	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—AKT1—atherosclerosis	4.91e-06	5.55e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—VEGFA—atherosclerosis	4.88e-06	5.51e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—VEGFA—atherosclerosis	4.86e-06	5.49e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—IL6—atherosclerosis	4.83e-06	5.46e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—STAT3—atherosclerosis	4.83e-06	5.46e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PPARG—atherosclerosis	4.82e-06	5.45e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—STAT3—atherosclerosis	4.81e-06	5.43e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—INS—atherosclerosis	4.73e-06	5.35e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—HMOX1—atherosclerosis	4.72e-06	5.34e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CXCL8—atherosclerosis	4.72e-06	5.34e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MMP9—atherosclerosis	4.7e-06	5.31e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—VEGFA—atherosclerosis	4.65e-06	5.25e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—NFKB1—atherosclerosis	4.65e-06	5.25e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—MAPK3—atherosclerosis	4.62e-06	5.22e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—ALB—atherosclerosis	4.6e-06	5.2e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—STAT3—atherosclerosis	4.6e-06	5.2e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MMP9—atherosclerosis	4.6e-06	5.19e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—MAPK3—atherosclerosis	4.59e-06	5.19e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MAPK8—atherosclerosis	4.57e-06	5.16e-05	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—AKT1—atherosclerosis	4.56e-06	5.16e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—AKT1—atherosclerosis	4.55e-06	5.15e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—NFKB1—atherosclerosis	4.55e-06	5.14e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—APOB—atherosclerosis	4.52e-06	5.11e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—IL6—atherosclerosis	4.49e-06	5.07e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—TGFB1—atherosclerosis	4.48e-06	5.06e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MAPK8—atherosclerosis	4.47e-06	5.05e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—AKT1—atherosclerosis	4.46e-06	5.04e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—TGFB1—atherosclerosis	4.46e-06	5.04e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—NOS3—atherosclerosis	4.4e-06	4.98e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GSTM1—atherosclerosis	4.4e-06	4.97e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—MAPK3—atherosclerosis	4.4e-06	4.97e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—ALB—atherosclerosis	4.34e-06	4.9e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—LPL—atherosclerosis	4.32e-06	4.88e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MMP9—atherosclerosis	4.27e-06	4.83e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—TGFB1—atherosclerosis	4.27e-06	4.82e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—NFKB1—atherosclerosis	4.23e-06	4.78e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—VEGFA—atherosclerosis	4.22e-06	4.76e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GPX1—atherosclerosis	4.21e-06	4.76e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—STAT3—atherosclerosis	4.17e-06	4.72e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MAPK8—atherosclerosis	4.15e-06	4.69e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—NOS3—atherosclerosis	4.15e-06	4.69e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—AKT1—atherosclerosis	4.14e-06	4.68e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—VEGFA—atherosclerosis	4.13e-06	4.66e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CD36—atherosclerosis	4.1e-06	4.64e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—STAT3—atherosclerosis	4.09e-06	4.62e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PTGS2—atherosclerosis	4.03e-06	4.55e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MAPK3—atherosclerosis	3.99e-06	4.51e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MAPK3—atherosclerosis	3.91e-06	4.41e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—MTHFR—atherosclerosis	3.89e-06	4.39e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—TGFB1—atherosclerosis	3.87e-06	4.37e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—VEGFA—atherosclerosis	3.84e-06	4.33e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PPARA—atherosclerosis	3.82e-06	4.31e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—STAT3—atherosclerosis	3.8e-06	4.29e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PTGS2—atherosclerosis	3.8e-06	4.29e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—TGFB1—atherosclerosis	3.79e-06	4.28e-05	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—AKT1—atherosclerosis	3.71e-06	4.19e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—AGT—atherosclerosis	3.7e-06	4.18e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MAPK3—atherosclerosis	3.63e-06	4.1e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—APOE—atherosclerosis	3.62e-06	4.09e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CAV1—atherosclerosis	3.59e-06	4.05e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—APOA1—atherosclerosis	3.58e-06	4.04e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—TGFB1—atherosclerosis	3.52e-06	3.98e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—IL6—atherosclerosis	3.38e-06	3.81e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—IL6—atherosclerosis	3.36e-06	3.79e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PIK3CG—atherosclerosis	3.27e-06	3.69e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—IL6—atherosclerosis	3.21e-06	3.63e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PPARG—atherosclerosis	3.15e-06	3.56e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—AKT1—atherosclerosis	3.11e-06	3.52e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—AKT1—atherosclerosis	3.1e-06	3.5e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—INS—atherosclerosis	3.09e-06	3.5e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—AKT1—atherosclerosis	2.97e-06	3.35e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—AKT1—atherosclerosis	2.93e-06	3.31e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—IL6—atherosclerosis	2.92e-06	3.29e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—IL6—atherosclerosis	2.86e-06	3.23e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—ALB—atherosclerosis	2.84e-06	3.2e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—NOS3—atherosclerosis	2.71e-06	3.07e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—AKT1—atherosclerosis	2.69e-06	3.04e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—AKT1—atherosclerosis	2.68e-06	3.03e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IL6—atherosclerosis	2.65e-06	3e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—AKT1—atherosclerosis	2.63e-06	2.98e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PTGS2—atherosclerosis	2.48e-06	2.8e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—AKT1—atherosclerosis	2.45e-06	2.77e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—AKT1—atherosclerosis	2.02e-06	2.29e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—AKT1—atherosclerosis	1.91e-06	2.16e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—AKT1—atherosclerosis	1.25e-06	1.41e-05	CbGpPWpGaD
